Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3644-3652

  Neggers, S J C M M ^a,b   Franck, S E ^a   De Rooij, F W M ^b   Dallenga, A H G ^b   Poublon, R M L ^b   Feelders, R A ^a,b   Janssen, J A M J L ^a,b   Buchfelder, M ^c   Hofland, L J ^a,b   Jorgensen J O L ^d   Van Der Lely, A J ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d Clinical Institute   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; MESSENGER RNA; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; GLUCURONOSYLTRANSFERASE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; SOMATOSTATIN; UGT1A1 ENZYME;

ACROMEGALY; ADULT; AGED; ARTICLE; CHOLESTASIS; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GENE EXPRESSION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSIS TUMOR; INJECTION SITE REACTION; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; SSTR1 GENE; SSTR2 GENE; SSTR5 GENE; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CASE REPORT; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; GENETICS; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TERTIARY CARE CENTER; TIME;

ACROMEGALY; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCURONOSYLTRANSFERASE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN; TERTIARY CARE CENTERS; TIME; TREATMENT OUTCOME;

EID: 84907610860     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2032     Document Type: Article

References (33)

1. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355:2558-2573.
2. Bates PR, Carson MN, Trainer PJ, Wass JA, UK National Acromegaly Register Study Group (UKAR-2). Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol (Oxf). 2008;68:136-142.
3. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419-3426.
4. Holdaway IM. Treatment of a cromegaly. Horm Res. 2004;62(suppl 3):79-92.
5. Sandret L, Maison P, Chanson P. Place of cabergol in einacromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96:1327-1335.
6. Neggers SJ, van der Lely AJ. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol. 2009;5:546-552.
7. van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97:1589-1597.
8. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 1985;313:1576-1580.
9. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-1177.
10. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-1759.
11. Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009;161(suppl 1):S3-S10.
12. Trainer PJ. ACROSTUDY: the first 5 years. Eur J Endocrinol. 2009;161(suppl 1):S19-S24.
13. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156:75-82.
14. Brue T, Castinetti F, Lundgren F, Koltowska-Häggström M, Petrossians P; ACRO STUDY investigators. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol. 2009;161(suppl 1):S11-S17.
15. Gutiérrez LP, Koltowska-Häggström M, Jönsson PJ, et al. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf. 2008;17:90-102.
16. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009;160:529-533.
17. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in a cromegaly. J Clin Endocrinol Metab. 2007;92:4598-4601.
18. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365:1644-1646.
19. Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary. 2011;14:253-258.
20. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93:3853-3859.
21. ∗28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab. 2010;95:2147-2154.
22. Elmlinger MW, Kühnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factorI (IGF-I) and IGF-bindingprotein3 (IGFBP-3). Clin Chem Lab Med. 2004;42:654-664.
23. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90:5627-5631.
24. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
25. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89:1577-1585.
26. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol. 2006;154:805-806.
27. Wang YY, Higham C, Kearney T, Davis JR, Trainer P, Gnanalingham KK. Acromegaly surgery in Manchester revisited-the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol (Oxf). 2012;76:399-406.
28. van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164:325-333.
29. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab. 2008;93:3515-3518.
30. Hodish I, Barkan A. Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab. 2008;4:324-332.
31. Madsen M, Krusenstjerna-Hafstrøm T, Møller L, et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: arandomized clinical trial. J Clin Endocrinol Metab. 2012;97:1227-1235.
32. Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98:E66-E71.
33. Muto C, Chiba K, Suwa T. Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in Asian and Western acromegaly patients. J Clin Pharmacol. 2011;51:1628-1643.